Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  FibroGen, Inc.    FGEN

FIBROGEN, INC.

(FGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2021 01/21/2021 01/22/2021 01/25/2021 01/26/2021 Date
44.65(c) 44.62(c) 47.56(c) 49.59(c) 48.99 Last
490 882 439 514 761 178 787 827 961 699 Volume
+1.43% -0.07% +6.59% +4.27% -1.21% Change
More quotes
Financials (USD)
Sales 2020 217 M - -
Net income 2020 -158 M - -
Net Debt 2020 - - -
P/E ratio 2020 -29,4x
Yield 2020 -
Sales 2021 477 M - -
Net income 2021 -66,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -53,2x
Yield 2021 -
Capitalization 4 513 M 4 513 M -
Capi. / Sales 2020 20,8x
Capi. / Sales 2021 9,47x
Nbr of Employees 531
Free-Float 91,9%
More Financials
Company
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small... 
More about the company
Notations Surperformance© of FibroGen, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about FIBROGEN, INC.
01/08INSIDER TRENDS : Insider at FibroGen Sells Stock for Taxes Interrupting 90-Day B..
MT
2020FIBROGEN : Commences Phase 3 Trial of Pamrevlumab in Idiopathic Pulmonary Fibros..
MT
2020FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatme..
GL
2020Stocks Dragged Into The Red as New COVID-19 Strain From UK Prompts Travel Res..
MT
2020FibroGen Down; FDA Extends Review Period for Roxadustat
DJ
2020SECTOR UPDATE : Health Care Stocks Trade Lower Premarket Monday
MT
2020FIBROGEN : Provides Regulatory Update on Roxadustat
AQ
2020FIBROGEN : Update on US regulatory review of roxadustat in anaemia of chronic ki..
AQ
2020ASTRAZENECA : FDA Requests More Analysis for Approval of Roxadustat
DJ
2020ASTRAZENECA : US Regulator Extends Review Period For AstraZeneca's Anemia Drug F..
MT
2020FIBROGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020FDA EXTENDS REVIEW PERIOD FOR FIBROG : Shares Down Over 11% in Late Trade
MT
2020FibroGen Provides Regulatory Update on Roxadustat
GL
2020INSIDER TRENDS : FibroGen Insider Disposition Interrupting 90-Day Buy Trend
MT
2020INSIDER TRENDS : Insider Sale at FibroGen Slowing 90-Days of Buying
MT
More news
News in other languages on FIBROGEN, INC.
2019AUSBLICK VIFOR : Halbjahresumsatz von 868 Millionen Franken erwartet
2019PRÉVISIONS VIFOR : chiffre d'affaires semestriel atour de 868 millions
2019FIBROGEN : Jefferies s'attend à des informations importantes
2019WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Chart FIBROGEN, INC.
Duration : Period :
FibroGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FIBROGEN, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 61,88 $
Last Close Price 49,59 $
Spread / Highest target 83,5%
Spread / Average Target 24,8%
Spread / Lowest Target -11,3%
EPS Revisions
Managers and Directors
NameTitle
Enrique A. Conterno Chief Executive Officer & Director
James A. Schoeneck Chairman
Pat Cotroneo Chief Financial Officer & Senior VP-Finance
Michael Martinelli Senior Vice President-Technical Development
Elias Kouchakji Senior VP-Clinical Development & Drug Safety
Sector and Competitors
1st jan.Capitalization (M$)
FIBROGEN, INC.33.70%4 513
MODERNA, INC.40.71%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
IQVIA HOLDINGS INC.2.15%35 090
SEAGEN INC.2.84%32 583